Cbd seizure
Pro Research Analysisby 
Searched over 200M research papers for "cbd seizure"
Cannabidiol (CBD) and Seizure Management: A Comprehensive Overview
Introduction to CBD and Seizures
Cannabidiol (CBD), a non-psychoactive compound derived from the Cannabis sativa plant, has garnered significant attention for its potential therapeutic effects in managing seizures. Unlike tetrahydrocannabinol (THC), CBD does not produce euphoric effects, making it a promising candidate for treating various forms of epilepsy and seizure disorders.
CBD Efficacy in Lennox-Gastaut Syndrome (LGS)
Reduction in Drop Seizure Frequency
A pivotal study evaluated the efficacy of CBD as an add-on therapy for patients with Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy characterized by frequent drop seizures. The randomized, double-blind, placebo-controlled trial demonstrated that patients receiving CBD experienced a significantly greater reduction in monthly drop seizure frequency compared to those on placebo (44% vs. 22%)1. This suggests that CBD can be an effective adjunctive treatment for reducing seizure frequency in LGS patients.
CBD in Dravet Syndrome
Convulsive Seizure Reduction
Dravet syndrome, another severe form of epilepsy, has also shown responsiveness to CBD treatment. In a controlled trial involving children and adolescents with drug-resistant seizures, CBD significantly reduced convulsive seizure frequency compared to placebo3. This study underscores the potential of CBD to manage seizures in patients with Dravet syndrome, providing a viable option for those unresponsive to conventional antiepileptic drugs.
Long-term Safety and Efficacy in Tuberous Sclerosis Complex (TSC)
Sustained Seizure Reduction
Long-term studies on CBD's efficacy in treating seizures associated with Tuberous Sclerosis Complex (TSC) have shown promising results. An open-label extension trial revealed that patients maintained a significant reduction in seizure frequency over 48 weeks, with a high proportion of patients reporting global improvement4. This indicates that CBD not only reduces seizure frequency but also has a sustained effect over extended periods.
Systematic Reviews and Meta-Analyses
Broad Efficacy Across Epileptic Conditions
A systematic review and meta-analysis of randomized controlled trials involving patients with Lennox-Gastaut syndrome and Dravet syndrome found that CBD significantly reduced seizure frequency and increased the proportion of patients achieving a 50% reduction in seizures5. These findings support the broad efficacy of CBD across different epileptic conditions, reinforcing its role as a valuable adjunctive therapy.
CBD in Veterinary Medicine
Seizure Management in Dogs
CBD's anticonvulsant properties extend beyond human medicine. Studies on dogs with idiopathic epilepsy have shown that CBD administration, in addition to conventional antiepileptic treatments, significantly reduced seizure frequency2 6. These findings highlight the potential of CBD as a treatment option for managing seizures in veterinary patients as well.
Mechanisms of Action
Multifactorial Mechanisms
The exact mechanisms by which CBD exerts its anticonvulsant effects are not fully understood but are believed to be multifactorial. Potential mechanisms include antagonism of G protein-coupled receptors, desensitization of transient receptor potential vanilloid type 1 channels, potentiation of adenosine-mediated signaling, and enhancement of GABAergic transmission8. These diverse mechanisms contribute to CBD's broad-spectrum efficacy in seizure management.
Conclusion
CBD has emerged as a promising adjunctive therapy for managing various forms of epilepsy and seizure disorders, including Lennox-Gastaut syndrome, Dravet syndrome, and Tuberous Sclerosis Complex. Clinical trials and systematic reviews consistently demonstrate its efficacy in reducing seizure frequency and improving patient outcomes. Additionally, CBD's potential extends to veterinary medicine, offering a new avenue for treating seizures in dogs. While further research is needed to fully elucidate its mechanisms of action and optimize dosing strategies, the current evidence supports the use of CBD as a valuable tool in the fight against epilepsy.
Sources and full results
Most relevant research papers on this topic
Cannabidiol (CBD) significantly reduces drop seizure frequency in Lennox-Gastaut syndrome (LGS): results of a multi-center, randomized, double-blind, placebo controlled trial (GWPCARE4) (S21.001)
CBD add-on therapy significantly reduces drop seizure frequency in Lennox-Gastaut syndrome patients, suggesting it may be an effective and well-tolerated treatment option.
RCT
Rigorous JournalRandomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy.
Oral CBD administration in dogs with intractable idiopathic epilepsy significantly reduced seizure frequency, but the proportion of dogs considered responders to treatment was similar between groups.
RCT
Animal Study
Highly CitedCannabidiol (CBD) reduces convulsive seizure frequency in Dravet syndrome: results of a multi-center, randomized, controlled trial (GWPCARE1) (CT.001)
CBD significantly reduces seizure frequency in children with Dravet syndrome, but has more frequent adverse events but is generally well-tolerated.
RCTRigorous JournalLong-term Safety and Efficacy of Cannabidiol (CBD) for the Treatment of Seizures in Patients with Tuberous Sclerosis Complex (TSC) in an Open-label Extension (OLE) Trial (GWPCARE6) (677)
Long-term CBD treatment is well-tolerated and effective in reducing seizures in patients with Tuberous Sclerosis Complex, with a high proportion reporting global improvement.
RCTRigorous JournalEfficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
CBD is an effective and safe adjunctive treatment for patients with epilepsy, reducing seizure frequency by at least 50% without causing significant withdrawal or adverse events.
Meta-AnalysisHighly CitedSafety and efficacy of cannabidiol-cannabidiolic acid rich hemp extract in the treatment of refractory epileptic seizures in dogs
CBD/CBDA-rich hemp extract at 2 mg/kg every 12 hours can effectively reduce epileptic seizure frequency in dogs when used in conjunction with other anti-seizure medications.
RCTAnimal StudyAnticonvulsive Effects and Pharmacokinetic Profile of Cannabidiol (CBD) in the Pentylenetetrazol (PTZ) or N-Methyl-D-Aspartate (NMDA) Models of Seizures in Infantile Rats
CBD has dose and model-dependent anti-seizure activity in infantile rats, with therapeutic doses not causing motor impairment.
Non-RCTAnimal StudyCannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Cannabidiol shows potential as an antiseizure medication for seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, but further research is needed to understand its mechanisms and pharmacokinetics in infants and children.
Rigorous JournalHighly Purified Cannabidiol for Epilepsy Treatment: A Systematic Review of Epileptic Conditions Beyond Dravet Syndrome and Lennox–Gastaut Syndrome
Highly purified CBD oil-based oral solution shows potential in treating epilepsy in patients with conditions beyond Dravet syndrome and Lennox-Gastaut syndrome, with common adverse events including somnolence, decreased appetite, diarrhea, and increased serum aminotransferases.
Systematic Review
Very Rigorous JournalCannabidiol, a Cannabis sativa constituent, inhibits cocaine-induced seizures in mice: Possible role of the mTOR pathway and reduction in glutamate release.
CBD protects against cocaine-induced seizures in mice, possibly through activation of the mTOR pathway and reduction in glutamate release.
Non-RCTAnimal StudyHighly Cited